|14th July 2020
During COVID-19 customer engagement is more challenging, but it has never been more important to get it right. So, how can you evolve the way you engage your stakeholders to ensure you’re speaking with ‘one voice’, while also delivering a seamless customer experience?
Blue Latitude Health, and our parent company Fishawack Health, have developed exclusive intellectual property, processes and tools to ensure you’re engaging customers in the right way. This combined with our experience in medical and commercial customer engagement ensures we deliver memorable engagements at any stage of the product lifecycle. View our service one-pagers below to find out how we can help solve your challenges whether you’re in a medical, brand, portfolio or an above brand role.
For more information, contact firstname.lastname@example.org
Our impactful messaging and strategic touchpoints ensure you deliver excellent customer experiences in every interaction, so your messages resonate today and you ensure brand loyalty for tomorrow.
Through our unique fusion of strategic vision, innovative thinking and scientific knowledge, we create exceptional experiences for healthcare professionals and patients in complex and evolving environments. Our partnerships with independent KOL networks across several therapy areas ensure you’re one step ahead of the competition.
We partner with you to ensure you harness the right technology and platforms, in the right way, and at the right time. We create emotive brands for your digital platforms to drive internal adoption globally, regionally, and locally to ensure you are communicating with one united voice across all stakeholder groups.
COVID-19 has drastically changed the lives of healthcare professionals. They are emotionally and physically drained and under huge amounts of pressure. They also need pharma’s help. Senior Consultant Pany Koizi outlines five principles for engaging with physicians during the pandemic.
|27th August 2020
Precision and personalised medicines are more than products, they are services in their own right. So, how should pharma approach this uncharted territory to ensure targeted therapies work for patients?